2. Academic Validation
  3. Discovery of a new class of p38 kinase inhibitors

Discovery of a new class of p38 kinase inhibitors

  • Bioorg Med Chem Lett. 2000 Sep 18;10(18):2047-50. doi: 10.1016/s0960-894x(00)00270-5.
J Dumas 1,  R Sibley,  B Riedl,  M K Monahan,  W Lee,  T B Lowinger,  A M Redman,  J S Johnson,  J Kingery-Wood,  W J Scott,  R A Smith,  M Bobko,  R Schoenleber,  G E Ranges,  T J Housley,  A Bhargava,  S M Wilhelm,  A Shrikhande
Affiliations

Affiliation

  • 1 Department of Chemistry Research, Bayer Research Center, West Haven, CT 06516, USA. [email protected]
PMID: 10999467 DOI: 10.1016/s0960-894x(00)00270-5
Abstract

The MAP kinase p38 has been implicated in cytokine signaling, and its inhibitors are potentially useful for the treatment of arthritis and osteoporosis. Novel small-molecule inhibitors of p38 kinase were derived from a combinatorial chemistry effort and exhibit activity in the nanomolar range. Very steep structure-activity relationships are observed within this class.

Figures